Ezabenlimab, PD-1 antibody
Ezabenlimab, PD-1 antibody
Search
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Connect the Docs
Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
Veterinarians: caught between excellence and exhaustion
Many children dream of becoming a veterinarian. What happens when that dream comes true?
In-Reach Africa initiatives successfully completed
We are proud to report the successful completion of Kuza Afya and Tiba Yako, two of our In-Reach Africa initiatives.
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Looking behind the scenes of Afrika Kommt!
Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Retinal Diseases
Retinal Diseases
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
EMPRISE
Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers